Atazanavir-associated nephrolithiasis: cases from the US food and drug administration's adverse event reporting system
Atazanavir-associated nephrolithiasis: cases from the US food and drug administration's adverse event reporting system
复制标题
DOI：
10.1097/qad.0b013e32813aee35
复制
发表时间：
2007-05-31
期刊：
影响因子：
3.8
通讯作者：
Birnkrant, Debra B.
中科院分区：
文献类型：
--
作者：
Chan-Tack, Kirk M.;Truffa, Melissa M.;Birnkrant, Debra B.
与阿扎那韦相关的肾结石风险尚未得到很好的表征。在美国食品和药物管理局的不良事件报告系统中搜索了接受基于阿扎那韦的治疗方案的艾滋病毒感染患者的肾结石报告。已查明30起案件。许多患者需要住院治疗，包括碎石术、输尿管支架植入术或内窥镜取石术。一些肾结石病例导致阿扎那韦停药。应告知医疗保健专业人员和患者，肾结石是阿扎那韦可能的不良事件。
The risk of nephrolithiasis associated with atazanavir is not well characterized. The US Food and Drug Administration's Adverse Event Reporting System was searched for reports of nephrolithiasis in HIV-infected patients taking an atazanavir-based regimen. Thirty cases were identified. Many patients required hospitalization for management, including lithotripsy, ureteral stent insertion, or endoscopic stone removal. Some cases of nephrolithiasis resulted in atazanavir discontinuation. Healthcare professionals and patients should be informed that nephrolithiasis is a possible adverse event with atazanavir.